The Gulf conflict has disrupted global supply chains, pushed...
REITs have changed the way commercial real estate is owned a...
What really powers the cloud? Behind every Google search, A...
What really powers the cloud? Behind every Google search, A...
Luxury real estate is one of the most talked-about segments ...
Pharmaceutical formulations manufacturer Claroid Pharmaceuticals has filed draft papers with Sebi for an initial public offering comprising a fresh issue of up to 74.50 lakh equity shares and an offer for sale of up to 51.50 lakh shares. Net proceeds from the fresh issue will fund a new manufacturing facility at the company's existing land in Ahmedabad, estimated to cost around INR 167.97 crore with an installed capacity of 15 lakh units per month, producing injectables, ampoules, vials and other formulations.
Pharmaceutical formulations manufacturer Claroid Pharmaceuticals has filed draft papers with the capital markets regulator Sebi to raise funds through an initial public offering. The Gujarat-based company's proposed IPO comprises a fresh issue of up to 74.50 lakh equity shares and an offer for sale of up to 51.50 lakh shares, aggregating to 1.26 crore equity shares, according to the draft red herring prospectus.
The net proceeds from the fresh issue will be used to fund capital expenditure for setting up a new manufacturing facility at the company's existing land in Ahmedabad. The proposed facility will manufacture injectables, ampoules, vials, dry powder, pre-filled syringes and eye-drop products, and is estimated to cost around INR 167.97 crore with an installed capacity of 15 lakh units per month.
Claroid Pharmaceuticals Ltd operates a manufacturing facility at Pirana, Ahmedabad, producing tablets, capsules and ointments. As per the draft papers, the company has developed 129 pharmaceutical formulations across therapeutic segments, including anti-infective, anti-inflammatory, anti-fungal, dermatology, pain management and gastrointestinal therapies. The company has an export presence across markets including Nigeria, Tanzania, Kenya, Myanmar, Zanzibar and Botswana, with Nigeria its largest export destination.
The company's revenue from operations rose to INR 169.72 crore in FY26 from INR 62.98 crore in FY24, registering a compound annual growth rate of 64.13 per cent. Claroid Pharmaceuticals also holds GMP certifications from regulatory authorities in Rwanda, Ghana, Tanzania and Zanzibar, and operates an in-house formulation and development facility alongside quality control, quality assurance and microbiology laboratories, supported by a network of more than 30 distributors across Africa.
Oneview Corporate Advisors and Valmiki Leela Capital are the book-running lead managers to the issue.
The planned Ahmedabad facility's focus on injectable formulations, including pre-filled syringes and vials, positions Claroid within a higher-value segment of pharmaceutical manufacturing compared with its existing oral-dosage product lines, reflecting a broader trend among Indian pharmaceutical companies of expanding into injectable manufacturing to capture greater export value, particularly in African markets where the company has already built a distribution network. The company's continued reliance on existing owned land in Ahmedabad for the new facility, rather than acquiring a fresh site, is expected to reduce both the capital outlay and the regulatory timeline associated with the expansion.
Claroid's revenue growth over the two years leading up to the filing, alongside its established regulatory approvals across multiple African markets, positions the company within a cohort of mid-sized Indian pharmaceutical exporters increasingly turning to public markets to fund capacity expansion into higher-margin, more technically demanding manufacturing categories. The injectables segment in particular requires stringent manufacturing controls and cleanroom infrastructure, representing a significant step up in capital and compliance requirements compared with the oral-dosage forms that have historically anchored the company's production base.
Source PTI
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026